Seeing Life Better Through Medicine
First Therapeutic Treatment for Pterygia
-------- New Ophthalmic Category

Cloudbreak Therapeutics is a clinical-stage biotechnology company focusing on ocular drug development.

Our mission is to help people see life better through medicine.

About Us

Cloudbreak Therapeutics is a clinical stage ophthalmic drug company, founded September 2015 in Irvine, CA, USA. Our team has diverse skill sets and extensive ocular drug R&D experience.

Our Focus

Cloudbreak Therapeutics has successfully formulated a potent multi-kinase inhibitor to block angiogenesis and fibrosis into a topical eye drop to treat anterior segment ophthalmic diseases. In addition, Cloudbreak Therapeutics has a unique Antibody-Drug Synergism Platform to treat posterior segment ophthalmic diseases.

Pipeline

Cloudbreak Therapeutics has a number of products at various stages of pre-clinical and clinical development that treat pterygium, pinguecula, meibomian gland dysfunction, glaucoma filtration surgery, adjunct therapy for glaucoma filtration surgery, age-related macular degeneration and diabetic retinopathy.

Successful EOP2 Meeting with FDA

We had a successful EOP2 meeting with the FDA for a disease modifying, first-in-class and first drug therapy to treat pterygium – a common ocular disease. In addition, we have strong IP protection with three issued patents from the United States Patent and Trademark Office (USPTO) to treat pterygium and hyperemia.